Eledon Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Tegoprubart showed non-inferior efficacy and a strong safety profile in kidney transplant studies, with promising results in islet cell transplantation and new Orphan Drug status for liver. Phase 3 planning is underway, targeting a large U.S. market, with a solid cash runway into next year.
-
Phase II and Ib studies demonstrated strong safety and promising efficacy for a new transplant therapy, with regulatory discussions and a phase III trial launch expected by year-end. Expansion into islet cell and xenotransplant programs is underway, supported by a solid cash runway through 2027.
Fiscal Year 2025
-
Tegoprubart, an anti-CD40 Ligand antibody, showed strong safety and noninferiority to tacrolimus in a phase II kidney transplant trial, with plans for a phase III study and expansion into islet cell and xenotransplant indications. Clinicians praised the safety profile, while investors focused on missed superiority.
-
The phase II BESTOW trial showed tegoprubart matched tacrolimus in preventing kidney transplant rejection, with numerically better kidney function and a superior safety profile, notably reducing diabetes, tremors, and hypertension. Plans are underway for a phase III trial and further long-term studies.
-
Tegoprubart aims to replace tacrolimus in kidney transplants, showing superior kidney function and iBOX scores in early trials, with a favorable safety profile and treatable rejection rates. The concentrated U.S. market and upcoming phase II/III milestones position the program for significant value creation.
-
Phase Ib data show tegoprubart is well tolerated in kidney transplant patients, with strong 12-month kidney function and high iBOX scores predicting >96% five-year graft survival. Improved outcomes versus standard care suggest potential to reduce transplant waitlist deaths.
-
Tegoprubart is advancing as a novel immunosuppressant with promising early data in kidney and islet cell transplantation, aiming to replace CNIs and expand into xenotransplantation. Key phase II results are expected in late 2024, with regulatory and commercial strategies in place to address a large, concentrated market.
-
Major data readouts for tegoprubart in renal and islet cell transplant are expected in 2024, with Phase 1b showing strong eGFR results and Phase 2 BESTOW aiming for superiority over tacrolimus. Expansion into xenotransplant and autoimmune indications is underway, with a robust safety profile and commercial potential.
-
Tegoprubart is advancing as a potential new standard in transplant immunosuppression, with phase II kidney data expected in Q4 and promising early results showing superior kidney function and safety. The company is expanding into other organ types and has secured funding through 2026.
Fiscal Year 2024
-
The company is advancing anti-CD40 ligand therapy for organ transplant rejection, with key phase 2 data in kidney and islet cell transplantation expected in the next year. Recent capital raise extends runway through 2026, and the program is differentiated by its focus and clinical profile.